Anisomycin

• UNSPSC Description:

  Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system[1]. Anisomycin is a JNK activator, which increases phospho-JNK[2][3]. Anisomycin is a bacterial antibiotic[4].

• Target Antigen:

  Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; JNK; Parasite

• Type:

  Natural Products

• Related Pathways:

  Anti-infection;Apoptosis;Cell Cycle/DNA Damage;MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/Anisomycin.html

• Purity:

  99.82

• Solubility:

  DMSO : ≥ 50 mg/mL|H2O : 4 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O[C@@H]1[C@@H](OC(C)=O)[C@@H](CC2=CC=C(OC)C=C2)NC1

• Molecular Weight:

  265.309

• References & Citations:

  [1]Lu Z, et al. Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-p53-ROS positive feedback loop in PC-12 cells.|[2]Zhengle Tang, et al. In vivo toxicological evaluation of Anisomycin. Toxicol Lett. 2012 Jan 5;208(1):1-11.|[3]Gao X, et al. Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKIIδ expression in the aged atrium. Cardiovasc Res. 2018 Apr 1;114(5):737-746.|[4]Synthesis Marina Macías-Silva, et al. Anisomycin is a Multifunctional Drug: More than Just a Tool to Inhibit Protein. Current Chemical Biology, 2010, 4, 124-132.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  22862-76-6